admin.bio

7
Jun

Biofortuna – your outsourcing partner of choice.

Having developed over 100 assays across a range of diverse applications, let Biofortuna be your outsourcing partner of choice.

25
Jul

Biofortuna unveils ampDRY™ air-dried master mix

Biofortuna (Liverpool, UK) – the international IVD contract research and contract manufacturing company – will be launching ampDRY™, its patent pending stabilised master mix for PCR applications, at the AACC Annual Scientific Meeting and Clinical Lab Expo in Chicago, July 29 to August 2. ampDRY hotstart master mix has been developed to enable complete end-stage or real-time PCR assays to

Read more

15
Aug

Biofortuna closes £1.6M funding round

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. The new funding –supported by current investor Foresight VCTs and members of the senior management team – will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical trials and commercialisation, as well as

Read more

24
Jan

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits. Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven

Read more

8
Jul

Biofortuna FDA Inspection Completed Successfully

Biofortuna have successfully completed an FDA site inspection to retain their FDA registered manufacturing site status. The inspection was carried out over several days in which the FDA thoroughly reviewed Biofortuna’s manufacturing, quality control and quality assurance procedures. Biofortuna manufactures 510k approved IVD kits for sale in the US for their molecular diagnostics division. An increasing number of contract service

Read more

18
May

Record year for Biofortuna Contract Services division

Biofortuna Ltd is pleased to announce a record year of growth for its IVD Contract Services division. This growth has been driven by the expansion of its service portfolio, together with increased demand for its core lyophilisation services. Biofortuna’s success stems from its specialist freeze-drying expertise and proprietary cryo­preservation technologies, allowing the stabilisation of complete PCR, isothermal amplification and immunoassay

Read more

26
Mar

Biofortuna invests in climate control facilities

Biofortuna Ltd, a diagnostics company based in Wirral UK, announces significant investment into its IVD Contract Manufacturing Division in order to support continued growth. Biofortuna’s new climate control system will allow for accurate control of environmental factors down to 5% relative humidity, resulting in unrivalled stability of lyophilised reagents. Packing in a low humidity environment ensures products are stored under

Read more

28
Jul

Biofortuna launches its new approach to custom IVD manufacture and development services

Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market. World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company

Read more

24
Feb

Biofortuna Ltd appoints new Chairman to lead next phase of growth

UK based molecular diagnostics company Biofortuna has appointed a new Chairman to lead the next phase of growth. Life sciences expert Ian Johnson will take on the role at Biofortuna with previous Chairman Mark Hurley remaining on the board as a Non-executive Director. Biofortuna, based in the Wirral, specialises in proprietary freeze-dried diagnostics and contract services. It recently announced a

Read more

29
Jan

Biofortuna Ltd closes a £1.5m funding round

Biofortuna Ltd, the UK based molecular diagnostics company specialising in its proprietary freeze-dried diagnostics and contract services, announces raising £1.5m in its latest funding round. The £1.5m funding was supported by all the company’s current investors; Foresight VCTs, Catapult Ventures, Enterprise Ventures, MSIF, private investors and management. The new funding is for Biofortuna to develop a portfolio of new molecular

Read more